Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

NCT04763616 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Natural Killer/T-cell Lymphoma
Relapsed Natural Killer/T-cell Lymphoma
Refractory Natural Killer/T-cell Lymphoma

Interventions

DRUG: Isatuximab
DRUG: Cemiplimab

Sponsor

Won Seog Kim

Collaborators

[object Object]